Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF)
Hepatic Encephalopathy, Acute-On-Chronic Liver Failure
About this trial
This is an interventional treatment trial for Hepatic Encephalopathy focused on measuring Hepatic Encephalopathy, Acute-On-Chronic Liver Failure, Neurological Dysfunction, Metabolomics, Systemic Inflammations, Branch Chain Amino Acid, bispectral index, Cerebral edema, Lactulose
Eligibility Criteria
Inclusion Criteria: Age 18-75 years Either gender Patients with ACLF (CANONIC definition) of any etiology with HE ≥grade 2 as per West-Haven Criteria Exclusion Criteria: Those who do not consent to participate in the study Patients with structural brain lesions or stroke Inability to obtain informed consent from patient or relatives Severe preexisting cardiopulmonary disease Renal dysfunction (S. Creatinine ≥ 2mg/dL) Pregnancy/Lactation Post liver transplant patients HIV infection Patients who are on psychoactive drugs, like sedatives or antidepressants Patients who are too sick to carry out the protocol.
Sites / Locations
- Dr. Madhumita PremkumarRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Experiential Arm
Comparator Arm
Drug: iv Branch Chain Amino Acid + Lactulose Intravenous Branched Chain Amino Acids - 500mL once daily for 3 days plus Lactulose
Drug: Lactulose + Placebo